NASDAQ
49.37USD
-0.63 (-1.26%)
We have scored 12 news catalysts on Scholar Rock Holding Corporation (SRRK) over the past 12 months. The biggest single-day move next to one of them came Mar 28, 2026, when SRRK closed −3.6%: “Scholar Rock: From Manufacturing Hurdle To Commercial Muscle, Maintaining Buy Rating”. Coverage across the window leans positive (average ticker sentiment +0.13). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.9B
P/E
—
EPS
—
Beta
0.68
52W range
27.07-61.76
Day range
48.59–50.62
Open
50.01
Prev close
50.00
Volume
3.7M
Avg volume
1.4M
Dividend
0.00
IPO
2018-05-25
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Scholar Rock Holding Corporation — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SRRK: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
